patient | Page 51 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

patient

Order Patient Educational Materials

Intro: 
<p>All of our materials are written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure diseases.</p>
Patient Guides
AAMDSIF patient guides are complete resources, written and reviewed by recognized medical professionals who are experts in bone marrow failure disease.
Fact Sheets
AAMDSIF Fact Sheets are one or two page sources of information on diverse subjects related to bone marrow failure disease.
Research Summaries for Patients
AAMDSIF Research Summaries are clearly written summaries of the most recent research on rare blood cancers and bone marrow failure diseases presented at the most prestigious and important international scientific gatherings.
Aplastic Anemia Toolkit
To learn more, see our Aplastic Anemia Toolkit page.
MDS Toolkit
To learn more, see our MDS Toolkit page.
PNH Toolkit
To learn more, see our PNH Toolkit page.
Required Information
Please provide us with the following information to complete your request.
Optional Information
In order to keep you informed with relevant news, events, and updates, we ask that you provide us with this optional information.
Special Instructions
If you require multiple copies of any of these documents, please make note of which documents, and the specific quantities desired here.

Ravulizumab-cwvz

Ravulizumab-cwvz (Ultomiris®) is a drug approved by the U.S. Food and Drug Administration (FDA) in 2018 to treat PNH. ULTOMIRIS® is a long-acting C5 inhibitor that works by inhibiting the C5 protein in the terminal complement cascade.  ULTOMIRIS® is a prescription medicine called a